Enhanced Prediction Model for Major Adverse Events Following Acute Myocardial Infarction

Condition(s) studied

Investigational drug(s) / intervention(s)

Percutaneous coronary intervention: Percutaneous coronary intervention

Study summary

Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide. Although early revascularization has markedly improved short-term outcomes, the incidence of major adverse cardiovascular events after the index event remains unacceptably high, posing a formidable clinical challenge. Contemporary risk-stratification instruments rely predominantly on a restricted set of conventional clinical variables and therefore fail to capture the full spectrum of individual pathophysiological complexity. To overcome these limitations, the present investigation aims to develop a post-AMI prognostic model that integrates comprehensive multimodal data.

Eligibility

Primary outcome measure(s)

• Recurrent myocardial infarction or cardiac death — At 24-month Follow-up
  Patients received recurrent myocardial infarction or cardiac death
• Diagnostic performance — At 24-month follow-up
  Diagnostic performance of the AI-driven multimodal predictive model: area under the receiver-operating characteristic curve (AUC), sensitivity, specificity, overall accuracy, positive predictive value (PPV), and negative predictive value (NPV).
• MACE at 24 months — At 24-month follow-up
  Major adverse cardiovascular events, defined as a compisite of cardiac death, myocardial infarction, target vessel revascularization.

Trial sites (1)

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition